These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22196480)

  • 1. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
    Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
    J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decoding the dynamics of BCL9 triazole stapled peptide.
    Gaikwad V; Choudhury AR; Chakrabarti R
    Biophys Chem; 2024 Apr; 307():107197. PubMed ID: 38335808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
    Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
    Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
    Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
    Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
    Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
    Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W
    Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Zhang M; Wang Z; Zhang Y; Guo W; Ji H
    J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors.
    Zhang M; Wisniewski JA; Ji H
    Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.
    Sustmann C; Flach H; Ebert H; Eastman Q; Grosschedl R
    Mol Cell Biol; 2008 May; 28(10):3526-37. PubMed ID: 18347063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Wang Z; Zhang M; Luo W; Zhang Y; Ji H
    J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
    Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
    Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
    Trabocchi A; Menchi G; Cini N; Bianchini F; Raspanti S; Bottoncetti A; Pupi A; Calorini L; Guarna A
    J Med Chem; 2010 Oct; 53(19):7119-28. PubMed ID: 20809642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
    El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
    Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient microwave assisted synthesis of novel 1,2,3-triazole-sucrose derivatives by cycloaddition reaction of sucrose azides and terminal alkynes.
    Potewar TM; Petrova KT; Barros MT
    Carbohydr Res; 2013 Sep; 379():60-7. PubMed ID: 23872329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
    Li Z; Zhang M; Teuscher KB; Ji H
    J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.
    Shen LA; Peng X; Bao Y; Liu C; Zhang H; Li J; Zhu D; Zhang Q
    Eur J Med Chem; 2023 Feb; 247():115075. PubMed ID: 36599228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facile entry into triazole fused heterocycles via sulfamidate derived azido-alkynes.
    Sai Sudhir V; Phani Kumar NY; Nasir Baig RB; Chandrasekaran S
    J Org Chem; 2009 Oct; 74(19):7588-91. PubMed ID: 19725506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
    de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
    Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction.
    Wang Z; Zhang M; Thompson HM; Ji H
    ACS Med Chem Lett; 2022 May; 13(5):865-870. PubMed ID: 35586435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.